Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies

Clinical Transplantation

Volumn 20, Issue 4, 2006, Pages 496-503

  Kim, Inho ^a   Yoon, Sung Soo ^a   Lee, Kyung Hun ^a   Keam, Bhumsuk ^a   Kim, Tae Min ^a   Kim, Jin Soo ^a   Kim, Hoon Gu ^a   Oh, Myoung Don ^a   Han, Kyou Sup ^a   Park, Myoung Hee ^a   Park, Seonyang ^a   Kim, Byoung Kook ^a  

^a Seoul National University   (South Korea)

Author keywords

Allogeneic stem cell transplantation; Hematological malignancy; Reduced intensity conditioning; Youths

Indexed keywords

BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; HEPARIN; HLA ANTIGEN; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INCIDENCE; INFECTION PREVENTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NEUTROPHIL COUNT; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; TREATMENT OUTCOME; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MELPHALAN; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33745632085     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00512.x     Document Type: Article

References (22)

1. Gale RP, Champlin RE. How dose bone marrow transplantation cure leukemia? Lancet 1984: 2: 28.
2. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995: 86: 2041.
3. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998: 91: 756.
4. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft versus leukemia without myeloablative therapy. Blood 1997: 89: 4531.
5. Alyea EP, Kim HT, Ho V et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 yr of age. Blood 2005: 105: 1810.
6. Sorror ML, Maris MB, Storer B et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplantation comorbidities. Blood 2004: 104: 961.
7. Diaconescu R, Flowers CR, Storer B et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004: 104: 1550.
8. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Tripp-Villanueva F et al. Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia. Stem Cells Dev 2004: 13: 571.
9. Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringden O. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 2004: 78: 1014.
10. Valcarcel D, Martino R, Sureda A et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005: 74: 144.
11. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-conditioning preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001: 97: 631.
12. Nakajima H, Oki M, Kishi K et al. Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies. Clin Lab Haematol 2003: 25: 383.
13. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001: 97: 3390.
14. Kim I, Park S, Kim BK et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia: A retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans. Clin Transplant 2001: 15: 167.
15. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975: 292: 895.
16. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986: 4: 42.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987: 40: 373.
18. Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol 1998: 16: 3796.
19. Hogan WJ, Maris M, Storer B et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004: 103: 78.
20. Schots R, Kaufman L, Van Riet I et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003: 17: 1150.
21. Essell JH, Thompson JM, Halvorson RD, Snyder MJ, Johnson RA, Rubinsak JR. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992: 79: 2784.
22. Junghanss C, Marr KA, Carter RA et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biol Blood Marrow Transplant 2002: 8: 512.